Tempus AI (NASDAQ:TEM | TEM Price Prediction) reports third-quarter results around Nov. 2. The company has a $1.5 billion Personalis (NASDAQ:PSNL) deal pending, and shares are down 20.36% over the past month.
Personalis is navigating a pivotal inflection, with Q2 2026 clinical volume surging 199% YoY and revenue up 33% sequentially to $22.4M, yet the company remains deeply unprofitable, posting a -150.2% operating margin and a -$31.7M net loss.
Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$0.32-21.5% vs -$0.26 | $26M+18.8% vs $22M |
Q3 2026 Aug 4, 2026 | -$0.30-13.9% vs -$0.26 | $22M+34.0% vs $17M |
Q2 2026 May 7, 2026 | -$0.29-26.1% vs -$0.23 | $15M+6.8% vs $14M |
Q1 2026 Feb 26, 2026 | -$0.26+16.1% vs -$0.31 | $17M+1.7% vs $17M |
Tempus AI (NASDAQ:TEM | TEM Price Prediction) reports third-quarter results around Nov. 2. The company has a $1.5 billion Personalis (NASDAQ:PSNL) deal pending, and shares are down 20.36% over the past month.
Leading securities law firm [url="]Bleichmar Fonti and Auld LLP[/url] announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that two oral presentations and two poster presentations featuring its NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) test will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. Highlights include a late-breaking oral presentation of NeXT Personal data for the C-POST Phase 3.
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the commercial launch of optional Real-Time Variant Tracker supplemental results in the NeXT Personal molecular residual disease (MRD) test report. These results identify clinically relevant resistance and therapeutically targetable variants over time, during NeXT Personal testing. Real-Time Variant Tracker includes variants with established clinical significance, includi.
Benchmark PSNL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Personalis, Inc. (PSNL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.98 | $1.6B | -13.46 | -17.69% | -147.74% | -49.52% | — | |
| $289.50 | $41.46B | -253.21 | 35.9% | -5.66% | -9.18% | — | |
| $145.14 | $19.25B | -40.22 | 32.88% | -37.93% | — | — | |
| $116.35 | $7.25B | -55.95 | 22% | -28.34% | -23.2% | — | |
| $210.01 | $31.77B | 36.14 | -0.78% | 19.72% | 31.45% | — | |
| $1.83 | $568.4M | -4.34 | 3.89% | -81.31% | -2618.51% | — |
Personalis, Inc. (PSNL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Personalis, Inc. (PSNL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jul 20, 2026·SEC
Jul 20, 2026·SEC
Get notified when PSNL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Personalis, Inc. (PSNL) stock FAQ — growth, dividends, profitability & financials explained
Personalis, Inc. (PSNL) reported $80.8M in revenue over the trailing twelve months. Revenue was $69.6M in fiscal year 2025. That is 641% more than the $9.4M of fiscal year 2017.
Personalis, Inc. (PSNL) grew revenue by 16.9% over the trailing twelve months, compared with the twelve months before.
No. Personalis, Inc. (PSNL) reported a net loss of $119.3M over the trailing twelve months.
Personalis, Inc. (PSNL) had a return on equity (ROE) of -49.5% over the trailing twelve months. A negative ROE means the company lost money over the period.
Personalis, Inc. (PSNL) had negative free cash flow of $107.7M over the trailing twelve months.